Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Combining conventional therapy with immunotherapy: A risky business?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Younger age at onset of colorectal cancer is associated with increased patient's delay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  • A Coosemans
  • A Vankerckhoven
  • T Baert
  • L Boon
  • H Ruts
  • M Riva
  • S Blagden
  • M Delforge
  • N Concin
  • M R Mirza
  • J A Ledermann
  • A du Bois
  • I Vergote
Vis graf over relationer

Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

TidsskriftEuropean journal of cancer (Oxford, England : 1990)
Sider (fra-til)41-44
Antal sider4
StatusUdgivet - maj 2019

Bibliografisk note

Copyright © 2019 Elsevier Ltd. All rights reserved.

ID: 59075179